^Voith K (1985). "The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats". Psychopharmacology. 85 (4): 405–9.
doi:
10.1007/BF00429654.
PMID3927334.
S2CID1573473.
^Koller WC, Fields JZ, Gordon JH, Perlow MJ (September 1986). "Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug". Neuropharmacology. 25 (9): 973–9.
doi:
10.1016/0028-3908(86)90190-5.
PMID3774130.
S2CID19175441.
^Weiner WJ, Factor SA, Sanchez-Ramos J, Berger J (1987). "A double-blind evaluation of ciladopa in Parkinson's disease". Movement Disorders. 2 (3): 211–7.
doi:
10.1002/mds.870020308.
PMID3332914.
S2CID31784301.
^Lieberman A, Gopinathan G, Neophytides A, Pasternack P, Goldstein M (May 1987). "Advanced Parkinson's disease: use of partial dopamine agonist, ciladopa". Neurology. 37 (5): 863–5.
doi:
10.1212/wnl.37.5.863.
PMID3574692.
S2CID25273606.